Acta chirurgiae orthopaedicae
et traumatologiae Čechoslovaca

Acta Chir Orthop Traumatol Cech. 2018; 85(1):17-21 | DOI: 10.55095/achot2018/002

Long-Term Effects of Intravenous Iloprost Therapy in Patients with Bone Marrow Oedema of the Knee JointOriginal papers

T. ZIPPELIUS^1,*, G. MATZIOLIS¹, C. PERKA², M. PUTZIER², P. STRUBE¹, E. RÖHNER¹

¹ Orthopaedic Department, University Hospital Jena, Campus Eisenberg, Germany

² Department of Traumatology and Orthopaedics, Charité University Hospital Berlin, Germany

PURPOSE OF THE STUDY:
Bone marrow oedema (BMO) syndrome is a multifactorial condition. Various conservative treatment options include analgesic therapy, immobilisation of the affected joint and/or systemic intravenous iloprost therapy. Many studies have confirmed the positive effect of iloprost therapy, but only after short-term follow-up. The purpose of this study was to show that treatment with iloprost leads to positive long-term functional and radiological outcomes for BMO of the knee.

MATERIAL AND METHODS:
Fifteen patients with BMO of the knee joint, ARCO stage 1-2, were included in this study. Various questionnaires, the Lysholm Score, the SF-36, WOMAC, Knee Society Score, and a visual analogue pain scale (VAS), were evaluated before and after iloprost therapy. All patients underwent MRI for radiological follow-up three months after treatment.

RESULTS:
Significant improvements were found in the Lysholm Score, SF-36, WOMAC and KSS. In 80% of patients, follow-up MRI after three months showed complete regression of the oedema. Three patients received additional surgery after a follow-up period of 33 ± 7 months.

CONCLUSIONS:
Based on the positive results of our study, we recommend treatment with iloprost for BMO of the knee in ARCO stage 1-2 patients.

Keywords: iloprost, bone marrow oedema, knee joint

Published: February 1, 2018  Show citation